These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1425982)

  • 1. Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs.
    Bohn H; Martorana PA; Schönafinger K
    Eur J Pharmacol; 1992 Sep; 220(1):71-8. PubMed ID: 1425982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential hemodynamic effects of the nitric oxide donor pirsidomine in comparison to SIN-1, nitroprusside and nitroglycerin.
    Arkonac BM; Kersten JR; Wynsen JC; Nijhawan N; Warltier DC
    Pharmacology; 1996 Feb; 52(2):92-100. PubMed ID: 8851630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiischemic effects of pirsidomine, a new nitric oxide donor.
    Martorana PA; Kettenbach B; Bohn H; Schönafinger K; Henning R
    Eur J Pharmacol; 1994 May; 257(3):267-73. PubMed ID: 8088346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirsidomine, a novel nitric oxide donor, suppresses ischemic arrhythmias in anesthetized pigs.
    Wainwright CL; Martorana PA
    J Cardiovasc Pharmacol; 1993; 22 Suppl 7():S44-50. PubMed ID: 7504768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term hemodynamic, anti-ischemic, and antianginal effects of pirsidomine, a new sydnonimine.
    Stengele E; Ruf G; Jähnchen E; Trenk D; Löffler K; Schulz W; Roskamm H
    Am J Cardiol; 1996 May; 77(11):937-41. PubMed ID: 8644642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of an NO-releasing pirsidomine derivative on coronary conductance during long-term administration.
    Bassenge E; Zanzinger J
    J Cardiovasc Pharmacol; 1993; 22 Suppl 7():S22-6. PubMed ID: 7504764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of oral molsidomine effects on ventricular function and dimensions in the conscious dog.
    Fiedler VB; Göbel H; Nitz RE
    Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):56-75. PubMed ID: 6409016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed.
    de Mey C; Breithaupt K; Seibert-Grafe M; Belz GG
    Eur J Clin Pharmacol; 1994; 46(4):295-9. PubMed ID: 7957511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic effects of molsidomine, isosorbide dinitrate, and nifedipine at rest and during exercise.
    Schartl M; Dougherty C; Rutsch W; Schmutzler H
    Am Heart J; 1985 Mar; 109(3 Pt 2):649-53. PubMed ID: 3838401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
    Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent effects of isosorbide-5-mononitrate on the venous, arterial and coronary arterial system of conscious dogs.
    Bassenge E; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Sep; 334(1):100-4. PubMed ID: 3785437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of isosorbide 5-mononitrate on cardiovascular function. (I). Effects on the left ventricular system].
    Kogi K; Saito T
    Nihon Yakurigaku Zasshi; 1985 May; 85(5):335-42. PubMed ID: 4029805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor.
    Bohn H; Brendel J; Martorana PA; Schönafinger K
    Br J Pharmacol; 1995 Apr; 114(8):1605-12. PubMed ID: 7599929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
    Kumagae H; Koiwaya Y; Tanaka K
    Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of catecholamines on cardiovascular actions of molsidomine in anesthetized dogs.
    Fiedler VB; Göbel H; Nitz RE
    J Cardiovasc Pharmacol; 1983; 5(3):491-8. PubMed ID: 6191151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses.
    Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E
    J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of oral and intravenous isosorbide mononitrate (5-MNi) in the acute phase of myocardial infarction].
    Rezende M
    Rev Port Cardiol; 1993 Mar; 12 Suppl 1():I35-8. PubMed ID: 8499118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled nitric oxide: effects on hemodynamics, myocardial contractility, and regional blood flow in dogs with mechanically induced pulmonary artery hypertension.
    Girard C; Fargnoli JM; Godin-Ribuot D; Dutheil V; Maitrasse B; Girardet P; Arvieux CC
    J Heart Lung Transplant; 1996 Jul; 15(7):700-8. PubMed ID: 8820786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs.
    Sponer G; Kühnle HF; Strein K; Bartsch W; Endele R; Dietmann K
    J Pharmacol Exp Ther; 1984 Jan; 228(1):235-9. PubMed ID: 6694105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of an orally active NO-releasing agent, CAS 936, and its active metabolite, 3754, on cardiac and coronary dynamics in normal conscious dogs and after pacing-induced heart failure.
    Wang J; Zhao G; Shen W; Ochoa M; Moore D; Hubbard JW; Hintze TH
    J Cardiovasc Pharmacol; 1993; 22 Suppl 7():S51-8. PubMed ID: 7504769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.